Bone Health in Premenopausal Chinese Patients after Adjuvant Chemotherapy for Early Breast Cancer

Background: In this cohort study, the objectives were to determine bone mineral density (BMD) and potential associated factors for bone health among young premenopausal patients after adjuvant chemotherapy. Methods: Eligibility criteria included premenopausal Chinese aged <45 years who had received adjuvant chemotherapy. At study entry, background demographics and menstrual history were collected; BMD was measured. Factors associated with reduced BMD and fracture risk were analyzed. Results: A total of 271 patients entered the study. The median time from breast cancer diagnosis to study entry was 5.0 years. The median ages at breast cancer diagnosis and at study entry were 41 and 47 years, respectively. The median BMDs for femoral neck (FN) and lumbar spine (LS) were 0.72 and 0.91 g/cm2, respectively; 40.2% had abnormal Z-scores (defined as ≤–1) and 50.2% had osteopenia/osteoporosis of either FN or LS. On multivariate analyses, factors that were identified to have a positive association with bone health (higher BMD) included higher family income (OR [95% CI] for LS = 1.573 [1.091–2.268]), taller stature (OR for LS = 2.975 [1.723–5.137]), and higher BMI (OR for FN = 2.156 [1.599–2.907]), while negatively associated factors included longer interval since last adjuvant treatment (OR for LS: 0.435 [0.250–0.757]), peri-/postmenopausal status at study entry (OR for LS = 0.443 [0.255–0.768]; OR for FN = 0.353 [0.205–0.609]), and having received adjuvant tamoxifen (OR for FN = 0.452 [0.243–0.841]). Conclusion: About 5 years after breast cancer diagnosis and adjuvant chemotherapy, >50% of premenopausal patients who had received adjuvant chemotherapy were detected to have osteopenia/osteoporosis and 40% had abnormal Z-scores for FN/LS.

[1]  W. Yeo,et al.  Quality of life of young Chinese breast cancer patients after adjuvant chemotherapy , 2018, Cancer management and research.

[2]  O. Bruyère,et al.  Skeletal health in breast cancer survivors. , 2017, Maturitas.

[3]  F. Mo,et al.  Profiles of lipids, blood pressure and weight changes among premenopausal Chinese breast cancer patients after adjuvant chemotherapy , 2017, BMC Women's Health.

[4]  Jie He,et al.  Cancer incidence and mortality in China in 2013: an analysis based on urbanization level , 2017, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[5]  W. Yeo,et al.  Chemotherapy-Related Amenorrhea and Menopause in Young Chinese Breast Cancer Patients: Analysis on Incidence, Risk Factors and Serum Hormone Profiles , 2015, PloS one.

[6]  G. Colditz,et al.  Results of the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial: A Behavioral Weight Loss Intervention in Overweight or Obese Breast Cancer Survivors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  W. Yeo,et al.  Risk factors and natural history of breast cancer in younger Chinese women. , 2014, World journal of clinical oncology.

[8]  C. Blomqvist,et al.  The effect of ovarian dysfunction on bone mineral density in breast cancer patients 10 years after adjuvant chemotherapy , 2014, Acta oncologica.

[9]  A. Partridge,et al.  Premature menopause in young breast cancer: effects on quality of life and treatment interventions. , 2013, Journal of thoracic disease.

[10]  M. Gnant,et al.  Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention? , 2012, Cancer treatment reviews.

[11]  E. Winer,et al.  Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. , 2011, European journal of cancer.

[12]  D. Cameron,et al.  Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency? , 2010, Breast Cancer Research and Treatment.

[13]  S. Cremers,et al.  Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. , 2010, The Journal of clinical endocrinology and metabolism.

[14]  Janet E Brown,et al.  Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer , 2010 .

[15]  L. Melton,et al.  A reference standard for the description of osteoporosis. , 2008, Bone.

[16]  S. Silverman,et al.  Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. , 2008, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[17]  S. Swain,et al.  Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Bilezikian,et al.  Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. , 2006, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[19]  C. Blomqvist,et al.  Short-Term Intermittent Intravenous Clodronate in the Prevention of Bone Loss Related to Chemotherapy-Induced Ovarian Failure , 2004, Breast Cancer Research and Treatment.

[20]  W. Sauerbrei,et al.  Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) , 2003, Osteoporosis International.

[21]  P. Pietschmann,et al.  [Osteoporosis in premenopausal women]. , 2002, Wiener medizinische Wochenschrift.

[22]  C. Blomqvist,et al.  Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. , 2001, European journal of cancer.

[23]  J. Manola,et al.  Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  C. Blomqvist,et al.  Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  T. Powles,et al.  Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Hart,et al.  Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. , 1990, British Journal of Cancer.